Cytokeratin 19 Antibody / CK19 Antibody

Cytokeratin 19 Antibody Overview

Cytokeratin 19 Antibody reagents target keratin 19 (KRT19), a type I intermediate filament protein expressed in simple and stratified epithelia. Unlike many cytokeratins, KRT19 lacks a partner type II keratin, giving it unique structural properties. KRT19 is broadly expressed in epithelial tissues, including the gastrointestinal tract, respiratory epithelium, and biliary system, making it a versatile epithelial marker.

KRT19 is widely used in pathology and oncology because of its diagnostic and prognostic value. Overexpression of KRT19 has been reported in carcinomas of the breast, thyroid, lung, liver, pancreas, and gastrointestinal tract. Serum fragments of KRT19, known as CYFRA 21-1, are established biomarkers in non-small cell lung carcinoma and other cancers. The Cytokeratin 19 Antibody is therefore indispensable in oncology, pathology, and biomarker discovery, while the CK19 Antibody provides broader support across developmental biology and translational research.

Why Choose Cytokeratin 19 Antibodies from NSJ Bioreagents?

NSJ Bioreagents offers Cytokeratin 19 Antibodies validated for immunohistochemistry, western blotting, immunofluorescence, ELISA, and flow cytometry. Each Cytokeratin 19 Antibody undergoes rigorous testing to ensure specificity, reproducibility, and minimal background staining.

By selecting Cytokeratin 19 Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and consistency. Our antibodies deliver strong epithelial staining in tissue biopsies, reproducible detection in lysates, and reliable results across research and diagnostic platforms. Comprehensive datasheets, recommended controls, and validated protocols ensure reproducibility in both discovery and clinical workflows.

Applications of Cytokeratin 19 Antibodies

The Cytokeratin 19 Antibody supports a wide range of biomedical and clinical applications.

1) Oncology and Tumor Biology

• Cytokeratin 19 Antibodies highlight KRT19 expression in breast, thyroid, lung, and liver cancers.

• The Cytokeratin 19 Antibody helps confirm epithelial lineage in carcinoma biopsies.

• CK19 Antibody reagents are used in biomarker validation for cancer prognosis and therapy monitoring.

2) Pathology and Diagnostics

• Cytokeratin 19 Antibodies are central to immunohistochemical panels for tumor subtyping.

• The Cytokeratin 19 Antibody supports detection of micrometastases in sentinel lymph nodes.

• CK19 Antibody reagents provide diagnostic clarity in thyroid and gastrointestinal pathology.

3) Biomarker Research and Translational Medicine

• Cytokeratin 19 Antibodies support studies of CYFRA 21-1 as a serum biomarker.

• The Cytokeratin 19 Antibody validates biomarkers in lung and liver cancer diagnostics.

• CK19 Antibody reagents are applied in clinical trials linking KRT19 expression to outcomes.

4) Developmental and Stem Cell Biology

• Cytokeratin 19 Antibodies track epithelial lineage specification during development.

• The Cytokeratin 19 Antibody validates differentiation in organoid and stem cell models.

• CK19 Antibody reagents support regenerative medicine involving epithelial tissues.

5) Infectious Disease and Inflammation

• Cytokeratin 19 Antibodies highlight epithelial remodeling during chronic infections.

• The Cytokeratin 19 Antibody supports studies into inflammation-driven carcinogenesis.

6) Translational and Clinical Research

• Cytokeratin 19 Antibodies are applied in precision oncology for patient stratification.

• The Cytokeratin 19 Antibody supports biomarker-driven therapeutic development.

• CK19 Antibody reagents provide reproducibility in translational workflows.

Why Are Cytokeratin 19 Antibodies Important?

KRT19 is one of the most versatile epithelial markers, with roles in biology, diagnostics, and oncology. The Cytokeratin 19 Antibody equips researchers with a precise tool for detecting this protein, while the CK19 Antibody extends its use into translational and clinical settings.

In oncology, Cytokeratin 19 Antibodies help identify carcinoma lineage, detect micrometastases, and validate prognostic biomarkers. In pathology, the Cytokeratin 19 Antibody confirms epithelial origin in complex diagnostic cases. In translational medicine, CK19 Antibody reagents link laboratory discoveries with clinical biomarkers like CYFRA 21-1.

Clinically, Cytokeratin 19 immunostaining and serum fragment assays remain indispensable in cancer diagnostics. Cytokeratin 19 Antibodies ensure reproducibility, diagnostic confidence, and translational relevance, bridging research with patient care.

Conclusion

Cytokeratin 19 is a broadly expressed keratin with major importance in oncology and diagnostics. The Cytokeratin 19 Antibody provides validated tools for detecting KRT19 in pathology, oncology, and developmental biology, while the CK19 Antibody supports biomarker discovery and translational applications. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing epithelial research and improving clinical outcomes.